Trial · NCT04097028
Adverse events30
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 30
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anemia | Blood and lymphatic system disorders | Treatment (TAS-102, Oxaliplatin) | 2 | 22 | 2 |
| other | Sinus tachycardia | Cardiac disorders | Treatment (TAS-102, Oxaliplatin) | 3 | 22 | 3 |
| other | Abdominal pain | Gastrointestinal disorders | Treatment (TAS-102, Oxaliplatin) | 3 | 22 | 3 |
| other | Bloating | Gastrointestinal disorders | Treatment (TAS-102, Oxaliplatin) | 2 | 22 | 2 |
| other | Constipation | Gastrointestinal disorders | Treatment (TAS-102, Oxaliplatin) | 11 | 22 | 11 |
| other | Diarrhea | Gastrointestinal disorders | Treatment (TAS-102, Oxaliplatin) | 9 | 22 | 9 |
| other | Dyspepsia | Gastrointestinal disorders | Treatment (TAS-102, Oxaliplatin) | 2 | 22 | 2 |
| other | Flatulence | Gastrointestinal disorders | Treatment (TAS-102, Oxaliplatin) | 2 | 22 | 2 |
| other | Mucositis oral | Gastrointestinal disorders | Treatment (TAS-102, Oxaliplatin) | 3 | 22 | 3 |
| other | Nausea | Gastrointestinal disorders | Treatment (TAS-102, Oxaliplatin) | 13 | 22 | 13 |
| other | Oral dysesthesia | Gastrointestinal disorders | Treatment (TAS-102, Oxaliplatin) | 2 | 22 | 2 |
| other | Vomiting | Gastrointestinal disorders | Treatment (TAS-102, Oxaliplatin) | 8 | 22 | 8 |
| other | Fatigue | General disorders | Treatment (TAS-102, Oxaliplatin) | 13 | 22 | 13 |
| other | Fever | Gastrointestinal disorders | Treatment (TAS-102, Oxaliplatin) | 3 | 22 | 3 |
| other | Infusion related reaction | Injury, poisoning and procedural complications | Treatment (TAS-102, Oxaliplatin) | 4 | 22 | 4 |
| other | Lymphocyte count decreased | Investigations | Treatment (TAS-102, Oxaliplatin) | 2 | 22 | 2 |
| other | Neutrophil count decreased | Investigations | Treatment (TAS-102, Oxaliplatin) | 5 | 22 | 5 |
| other | Platelet count decreased | Investigations | Treatment (TAS-102, Oxaliplatin) | 3 | 22 | 3 |
| other | White blood cell decreased | Investigations | Treatment (TAS-102, Oxaliplatin) | 2 | 22 | 2 |
| other | Anorexia | Metabolism and nutrition disorders | Treatment (TAS-102, Oxaliplatin) | 6 | 22 | 6 |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04097028/events